Related Experiment Video
Updated: May 26, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
How psychotropic polypharmacy in schizophrenia begins: a longitudinal perspective
M Shinfuku1, H Uchida, C Tsutsumi
1Department of Neuropsychiatry, Keio University School of Medicine, and Department of Psychiatry, Komagino Hospital, Tokyo, Japan.
Pharmacopsychiatry
|December 17, 2011
Summary
Psychotropic polypharmacy is common in schizophrenia treatment, often starting early and persisting. This study details when and how these medication combinations begin in clinical practice.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Pharmacy
Background:
- Schizophrenia treatment frequently involves psychotropic polypharmacy.
- The initiation patterns and timing of psychotropic polypharmacy are not well-documented.
Purpose of the Study:
- To investigate the longitudinal prescription patterns of concomitant psychotropics in schizophrenia patients.
- To determine the timing and frequency of polypharmacy initiation in relation to antipsychotic prescriptions.
Main Methods:
- Systematic chart review of 300 schizophrenia patients.
- Analysis of 2-year prescription data, including a subgroup of 100 psychotropic-naive patients.
Main Results:
- Polypharmacy occurred in 79% of patients within 2 years.
- Commonly added medications included hypnotics (56.7%), anxiolytics (49.7%), and antidepressants (21.3%).
- In psychotropic-naive patients, add-on medications were initiated after a mean of 1.5-2.3 antipsychotics, often within months.
Conclusions:
- Clinical practice often deviates from treatment algorithms regarding polypharmacy.
- Polypharmacy is frequently initiated early in schizophrenia treatment, sometimes without adequate trials of monotherapy.
- Once initiated, polypharmacy tends to be maintained long-term.
More Related Videos
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:29Psychological and Sociocultural Causes of Schizophrenia
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
01:29Biological Causes of Schizophrenia
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.